Puromycin aminonucleoside‐induced podocyte injury is ameliorated by the Smad3 inhibitor SIS3

Lina Jiang, Hong Cui, Jie Ding, Aijun Yang, Yingchao ZhangFEBS 2020 · DOI

TL;DR

This study investigates the role of Smad3 signaling in puromycin aminonucleoside (PAN)-induced podocyte injury, a key factor in nephrotic syndromes. Researchers found that inhibiting Smad3 with SIS3 effectively protected podocytes from PAN-induced damage by restoring cytoskeletal integrity and reducing the expression of transgelin, a protein implicated in podocyte injury. This suggests Smad3 and transgelin are critical players in PAN-induced podocyte dysfunction and potential therapeutic targets.

What Problem Does This Paper Address?

Podocytes are specialized cells in the kidney glomerulus crucial for filtering blood. Injury to these cells, often seen in nephrotic syndromes, leads to foot process effacement and fusion, resulting in proteinuria. Puromycin aminonucleoside (PAN) is a common experimental tool to induce podocyte injury and mimic aspects of these diseases. While various signaling pathways have been implicated in PAN-induced podocyte damage, the specific role of the Smad3 pathway and its downstream targets, particularly in relation to cytoskeletal proteins like transgelin, remained unclear. Understanding these mechanisms is vital for developing targeted therapies to prevent or reverse podocyte injury and proteinuria.

Methods

The researchers utilized a well-established in vitro model of podocyte injury using the MPC5 cell line, which is a conditionally immortalized mouse podocyte cell line.

  • PAN-induced injury model: MPC5 cells were treated with PAN to mimic podocyte damage.
  • Smad3 Inhibition: The specific Smad3 inhibitor, SIS3, was used to block Smad3 signaling.
  • Western Blotting: This technique was employed to quantify the expression levels of various proteins, including transgelin, cleaved caspase-3 (an apoptosis marker), phosphorylated Smad3 (p-Smad3), total Smad3, phosphorylated JAK/STAT3 (p-JAK/p-STAT3), c-myc, p15INK4B, and the housekeeping protein β-actin.
  • Immunofluorescence Microscopy: This method was used to visualize the distribution of F-actin (a key cytoskeletal protein) and transgelin within the podocytes. This allowed for the assessment of cytoskeletal integrity and the colocalization of transgelin with F-actin.
  • TGF-β1 Stimulation: To further explore the link between TGF-β1 signaling and transgelin, podocytes were directly stimulated with TGF-β1, and the effects were analyzed with and without SIS3 treatment.

Datasets

Not discussed in the paper. The study relies on in vitro experiments using cultured MPC5 cells.

Key Insights and Ideas

  • Smad3 is a key mediator of PAN-induced podocyte injury: The study strongly implicates the Smad3 signaling pathway in the development of podocyte damage caused by PAN.
  • Transgelin is a critical downstream target of Smad3 in podocyte injury: The research highlights transgelin as a protein whose expression is significantly upregulated by PAN and is directly influenced by Smad3 signaling. Its colocalization with F-actin suggests a role in cytoskeletal disruption.
  • SIS3 offers a protective effect: The Smad3 inhibitor SIS3 demonstrated a significant ability to reverse the detrimental effects of PAN on podocytes, including cytoskeletal disorganization and transgelin upregulation.
  • TGF-β1 pathway activation is linked to transgelin and Smad3: The findings suggest that PAN activates the TGF-β1 signaling pathway, which in turn drives Smad3 activation and subsequent transgelin expression.
  • Cytoskeletal integrity is paramount: The study underscores the importance of maintaining the normal architecture of F-actin for podocyte function and how its disruption contributes to injury.

Key Results

  • PAN treatment led to significant damage to podocyte cytoskeleton, characterized by F-actin depolymerization and disappearance, and FP retraction.
  • Transgelin expression was markedly increased in PAN-treated podocytes and colocalized with F-actin.
  • Smad3 phosphorylation (p-Smad3) was also significantly induced by PAN.
  • Treatment with the Smad3 inhibitor SIS3 reversed the PAN-induced F-actin disorganization and reduced transgelin expression.
  • SIS3 treatment also attenuated the upregulation of other proteins associated with PAN injury, including p15INK4B, phosphor-JAK/STAT3, cleaved caspase 3, and c-myc.
  • Direct stimulation of podocytes with TGF-β1 mimicked some effects of PAN, inducing transgelin and p-Smad3 expression, which were also inhibited by SIS3.

Limitations and Future Work

  • In vitro model: The study was conducted using an in vitro cell culture model. While valuable, these models do not fully replicate the complex in vivo environment of the kidney. Future work should validate these findings in animal models of kidney disease and in human samples.
  • Specific mechanisms of transgelin's role: While the study shows transgelin is upregulated and colocalizes with F-actin, its precise functional role in podocyte injury and FP retraction requires further investigation.
  • Broader therapeutic potential: The authors suggest that Smad3 and transgelin are potential therapeutic targets. Further research is needed to explore the efficacy and safety of targeting these pathways in clinical settings for various proteinuric kidney diseases.
  • Interaction with other pathways: The study touches upon JAK/STAT3 and c-myc, but a more comprehensive understanding of how Smad3 signaling interacts with these and other pathways in podocyte injury would be beneficial.

Summary updated

Abstract

Smad3 signaling and transgelin expression are often activated during puromycin aminonucleoside (PAN)-induced podocyte injury. Here, we investigated whether the Smad3 inhibitor SIS3 can ameliorate damage to injured podocytes. A model of PAN-induced podocyte injury was constructed using the MPC5 cell line. The effects of SIS3 on the expression of the podocyte cytoskeletal proteins transgelin, p15<sup>INK4B</sup> , phosphor-smad3, phosphor-JAK/stat3, the apoptotic marker cleaved caspase 3, and c-myc were investigated using western blot. The distribution of F-actin in PAN-induced podocyte injury was observed under an immunofluorescence microscope. PAN-induced podocyte injury altered the distribution of F-actin and transgelin, and colocalization of these two proteins was observed. Transgelin expression and Smad3 phosphorylation were increased in the MPC5 cell line with prolonged PAN treatment. In addition, c-myc expression, p15<sup>INK4B</sup> , and JAK phosphorylation were all increased after treatment with PAN. Treatment with the Smad3 inhibitor SIS3 reversed these phenomena and protected against PAN-induced podocyte injury. Moreover, stimulating podocytes directly with TGFβ-1 also led to enhanced expression of transgelin or phosphor-JAK/stat3, and this could be inhibited by SIS3. In conclusion, transgelin expression was induced through the Smad3 signaling pathway during PAN-induced podocyte injury, and the resulting abnormal distribution of F-actin and the enhanced expression of transgelin could be reversed by blockade of this pathway.
BibTeX
@inproceedings{jiang2020puromycin,
  author = {Lina Jiang and Hong Cui and Jie Ding and Aijun Yang and Yingchao Zhang},
  title = {{Puromycin aminonucleoside‐induced podocyte injury is ameliorated by the Smad3 inhibitor SIS3}},
  booktitle = {FEBS},
  year = {2020},
  doi = {10.1002/2211-5463.12916},
}
Figure